Steven Edward Landau

US Patent:

7125848, Oct 24, 2006

Filed:

Jun 10, 2004

Appl. No.:

10/865225

Inventors:

Matthew Oliver Fraser - Apex NC, US
Steven B. Landau - Wellesley MA, US
Edward C. Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A01N 37/18
A61K 38/00
C07K 14/00

US Classification:

514 12, 514 2, 530350

Abstract:

A method is provided for using Cav2. 2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.

US Patent:

20040198822, Oct 7, 2004

Filed:

Mar 22, 2004

Appl. No.:

10/805977

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Assignee:

Dynogen Pharmacueticals, Inc. - Boston MA

International Classification:

A61K031/195

US Classification:

514/561000

Abstract:

A method is provided for using subunit calcium channel modulators or other compounds that interact with the calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20050113421, May 26, 2005

Filed:

Nov 17, 2004

Appl. No.:

10/991051

Inventors:

Matthew Fraser - Apex NC, US
Steven Landau - Wellesley MA, US
Edward Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K031/4439
A61K031/426
A61K031/421
A61K031/4164

US Classification:

514340000, 514369000, 514376000, 514389000

Abstract:

A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

US Patent:

20050239890, Oct 27, 2005

Filed:

May 10, 2005

Appl. No.:

11/126062

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K031/195
A61K031/165

US Classification:

514561000, 514618000, 514617000

Abstract:

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, αδ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20060247311, Nov 2, 2006

Filed:

Apr 7, 2006

Appl. No.:

11/400666

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K 31/22
A61K 31/195
A61K 31/16

US Classification:

514551000, 514561000, 514626000

Abstract:

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, αδ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20060264509, Nov 23, 2006

Filed:

Mar 22, 2004

Appl. No.:

10/549829

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

International Classification:

A61K 31/195
A61K 31/165

US Classification:

514561000, 514621000

Abstract:

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, αδ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20060276542, Dec 7, 2006

Filed:

Mar 22, 2004

Appl. No.:

10/549998

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougermont NC, US

International Classification:

A61K 31/22
A61K 31/195
A61K 31/165
A61K 31/16

US Classification:

514551000, 514561000, 514621000, 514626000

Abstract:

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, αδ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20070060652, Mar 15, 2007

Filed:

Nov 13, 2006

Appl. No.:

11/598393

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K 31/195
A61K 31/165

US Classification:

514561000, 514618000

Abstract:

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, αδ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.